Literature DB >> 8606490

Characterization of the continuous cell line HepT1 derived from a human hepatoblastoma.

T Pietsch1, C Fonatsch, S Albrecht, H Maschek, H K Wolf, D von Schweinitz.   

Abstract

Hepatoblastoma is the most common malignant pediatric liver tumor. The molecular mechanisms involved in the pathogenesis of hepatoblastoma are unknown. Cell lines can be valuable tools in the study of tumor biology, but only few hepatoblastoma cell lines have been established. We explanted tumor tissue from human hepatoblastomas to generate cell lines. A continuous cell line (HepT1) was established from a human hepatoblastoma with predominant embryonal differentiation. The HepT1 cell line was characterized by immunohistochemistry, electron microscopy, cytogenetics, and molecular genetic analysis. In addition, the cultured cells were xenografted into nude mice and the resulting tumors compared with the original tumor. The cells grew in epithelial clusters, and expressed cytokeratins and alpha-fetoprotein. Injection of HepT1 cells into nude mice gave rise to serially transplantable subcutaneous tumors. The cell line as well as the xenotransplants displayed the phenotypic and genotypic characteristics of the primary tumor. Ultrastructural analysis demonstrated desmosomal junctions and the formation of bile canaliculi. Cytogenetic analysis showed a near tetraploid karyotype with structural and numerical aberrations of chromosomes 1p, 6, 9, 11q, 13q, 15p, and 20 and both single and double minute chromosomes. In PCR-based microsatellite analysis of chromosome arm 11p, a loss of heterozygosity at all informative loci including the WT-1 and IGF2 genes was detected. Intratumoral erythropoiesis, a characteristic feature of hepatoblastomas, was present in the primary tumor as well as in HepT1 xenotransplants. We therefore studied the expression of erythropoietic cytokines in these cells and found both erythropoietin and stem cell factor. The HepT1 cell line displays characteristic cellular and molecular features of hepatoblastoma and we believe it will be a valuable tool for studies on the biology and pathogenesis of hepatoblastoma as well as on the differentiation of hepatocyte progenitor cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8606490

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  25 in total

1.  p57(KIP2) is not mutated in hepatoblastoma but shows increased transcriptional activity in a comparative analysis of the three imprinted genes p57(KIP2), IGF2, and H19.

Authors:  W Hartmann; A Waha; A Koch; C G Goodyer; S Albrecht; D von Schweinitz; T Pietsch
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

2.  Characterization of genomic alterations in hepatoblastomas. A role for gains on chromosomes 8q and 20 as predictors of poor outcome.

Authors:  R G Weber; T Pietsch; D von Schweinitz; P Lichter
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

3.  Optimizing vector application for gene transfer into human hepatoblastoma cells.

Authors:  Steven W Warmann; Sorin Armeanu; Heike Heitmann; Peter Ruck; Guido Seitz; Johannes T Wessels; Marie-Luise Lemken; Ulrich M Lauer; Jörg Fuchs; Michael Bitzer
Journal:  Pediatr Surg Int       Date:  2006-07-29       Impact factor: 1.827

4.  In vitro gene targeting in human hepatoblastoma.

Authors:  Steven W Warmann; Sorin Armeanu; Heike Frank; Heike Buck; Florian Graepler; Marie-Luise Lemken; Heike Heitmann; Guido Seitz; Ulrich M Lauer; Michael Bitzer; Jörg Fuchs
Journal:  Pediatr Surg Int       Date:  2006-01       Impact factor: 1.827

5.  Apoptosis sensitizers enhance cytotoxicity in hepatoblastoma cells.

Authors:  Justus Lieber; Verena Ellerkamp; Julia Wenz; Bettina Kirchner; Steven W Warmann; Jörg Fuchs; Sorin Armeanu-Ebinger
Journal:  Pediatr Surg Int       Date:  2012-02       Impact factor: 1.827

6.  Pharmacological inhibition of beta-catenin in hepatoblastoma cells.

Authors:  V Ellerkamp; J Lieber; C Nagel; J Wenz; S W Warmann; J Fuchs; S Armeanu-Ebinger
Journal:  Pediatr Surg Int       Date:  2012-12-25       Impact factor: 1.827

7.  Novel patient-derived xenograft and cell line models for therapeutic testing of pediatric liver cancer.

Authors:  Beatrice Bissig-Choisat; Claudia Kettlun-Leyton; Xavier D Legras; Barry Zorman; Mercedes Barzi; Leon L Chen; Mansi D Amin; Yung-Hsin Huang; Robia G Pautler; Oliver A Hampton; Masand M Prakash; Diane Yang; Malgorzata Borowiak; Donna Muzny; Harsha Vardhan Doddapaneni; Jianhong Hu; Yan Shi; M Waleed Gaber; M John Hicks; Patrick A Thompson; Yiling Lu; Gordon B Mills; Milton Finegold; John A Goss; D Williams Parsons; Sanjeev A Vasudevan; Pavel Sumazin; Dolores López-Terrada; Karl-Dimiter Bissig
Journal:  J Hepatol       Date:  2016-04-23       Impact factor: 25.083

8.  Effect of duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) on hepatoblastoma cell lines.

Authors:  Carmen Eicher; Alexander Dewerth; Verena Ellerkamp; Joerg Fuchs; Sarah Schott; Sorin Armeanu-Ebinger
Journal:  Pediatr Surg Int       Date:  2013-02       Impact factor: 1.827

9.  In vitro evaluation of the Aurora kinase inhibitor VX-680 for Hepatoblastoma.

Authors:  Alexander Dewerth; Timo Wonner; Justus Lieber; Verena Ellerkamp; Steven W Warmann; Jörg Fuchs; Sorin Armeanu-Ebinger
Journal:  Pediatr Surg Int       Date:  2012-04-18       Impact factor: 1.827

10.  Effect of sorafenib combined with cytostatic agents on hepatoblastoma cell lines and xenografts.

Authors:  C Eicher; A Dewerth; J Thomale; V Ellerkamp; S Hildenbrand; S W Warmann; J Fuchs; S Armeanu-Ebinger
Journal:  Br J Cancer       Date:  2012-12-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.